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Ankylosing spondylitis is a chronic inflammatory condition that usually affects young men. Cardiac dysfunction and pulmonary
disease are well-known and commonly reported extra-articular manifestation, associated with ankylosing spondylitis (AS). AS has
also been reported to be specifically associated with aortitis, aortic valve diseases, conduction disturbances, cardiomyopathy and
ischemic heart disease. The pulmonary manifestations of the disease include fibrosis of the upper lobes, interstitial lung disease,
ventilatory impairment due to chest wall restriction, sleep apnea, and spontaneous pneumothorax. They are many reports detailing
pathophysiology, hypothesized mechanisms leading to these derangements, and estimated prevalence of such findings in the AS
populations. At this time, there are no clear guidelines regarding a stepwise approach to screen these patients for cardiovascular
and pulmonary complications.
1. Cardiac Manifestations of
Ankylosing Spondylitis
Introduction. Ankylosing spondylitis is a chronic and inflam-
matory condition, affecting the spine, sacroiliac, and periph-
eral joints. This entity most often affects young men and
may lead to spinal vertebral fusion. Human leukocyte antigen
(HLA)-B27 is present in the majority of patients with AS
and is reported to contribute to the pathophysiologic mani-
festations of this condition [1].
It has been estimated that cardiac manifestations in
patients with AS are found in 2–10% of patients. It was
initially in the 1930s when aortitis found in a group of
patients with spondylitis. It is widely accepted today that not
only is aortic pathology linked to AS, but there is also risk for
conduction defects, valvular regurgitation, and cardiomy-
opathy, associated with this entity [1]. This is especially
important, given that in many patients, cardiac changes may
begin prior to the onset of clinical symptoms [2, 3].
1.1. Valvular Disease. The presence of aortic root and valve
disease in ankylosing spondylitis is related to the duration of
the underlying disease. Aortic disease and aortic regurgita-
tion may, however, predate the onset of any joint symptoms,
and the presence of ankylosing spondylitis as an underlying
cause may not be initially appreciated [1].
One of the first pathophysiologic descriptions of valvular
disease in AS was put forward by Bulkley and Roberts, who
studied autopsy findings in eight patients with AS. They
noted aortic root dilatation along with fibrous proliferation
along the intima [4]. Further examination demonstrated a
cellular inflammatory process coupled with platelet aggre-
gation leading to endarteritis around the aortic root and
valve. This in turn stimulates fibroblast hyperactivity leading
to tissue thickening involving aortic annulus, cusps, aorto-
mitral junction along with the conduction system [5]. The
thickening of the valvular cusps, dilatation of the aortic root,
and abnormal cusp displacement via the thickened subaortic
tissue all lead to aortic regurgitation as seen in many patients
with AS [1].
Roldan et al. studied the root and valves in AS patients
(n = 44) using transthoracic echocardiography (TEE) and
found aortic root and valve disease in (82%) as compared
with control (27%). Other irregularities were aortic root
thickening, increased root stiffness and dilatation. Except for
the duration of AKS, aortic root disease and valve disease
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were unrelated to the activity, severity or therapy of AKS.
During followup of 25 patients over 39 months in this
study, in up to 24% new aortic root or valve abnormalities
developed, in 12% existing valve regurgitation worsened
significantly and in 20% abnormalities resolved. Twenty
percent of patients developed heart failure, underwent valve
replacement [5]. Aortic regurgitation is most commonly seen
in patients with AS; however, mitral regurgitation is also
known to occur, although less common [1]. The proposed
mechanism is basically a continuation of the fibrosis of the
subaortic tissues which can progress to reach the mitral
valve leaflet. Thereby, a stiffening and hence reduction
of the mitral valvular mobility occurs, eventually leading
to mitral regurgitation. Another potential mechanism for
mitral regurgitation may be as a result of severe aortic
regurgitation, leading to a hypertrophied left ventricle and
hence a distortion of the mitral valve apparatus [1].
1.2. Conduction and Rhythm Abnormalities. Conduction
abnormalities are amongst the most commonly observed
cardiac manifestations of patients with AS that usually
predate other cardiac manifestations such as valvular insuf-
ficiency [6]. In a study by Dik et al. they found a statistically
significant higher prevalence of AS patients with first-degree
AV block as well as an association of these blocks with the
duration of disease activity [7]. There have been two preva-
lent theories about the etiology of conduction disturbances
in patients with AS: inflammation in the intraventricular
septum leading to damage versus anomalies in the AV nodal
artery leading to AV node dysfunction [7]. Certainly, the
above processes may play hand in hand, given that both AV
blocks along with atrial and ventricular extra-systoles have
been reported [7, 8]. Interestingly, in the observational study
by Dik et al. they also report an increased finding of conduc-
tion disturbances in patients who are HLA-B27 positive, even
in patients without rheumatologic manifestations of AS [7].
Toussirot et al. found factors which highlight autonomic
nervous system derangements, in patients with AS [9]. For
example, there was a finding of a small but statistically sig-
nificant elevation in heart rates. This correlated with disease
severity, as measured by ESR and CRP levels [9]. Further-
more, an inability to maintain steady arterial blood pressures
with changes in position (i.e., supine to erect), was found.
Based on their findings, the group postulated that these
autonomic derangements may lead to conduction defects
and arrhythmias, thereby negatively impacting prognosis.
They further extrapolated that these subtle autonomic find-
ings may be evident prior to more concrete EKG findings,
hence a clinical practice implication [10]. Contradictory
to this report is a paper two years later, by Yildirir et
al. refuting autonomic dysfunction in the AS population
[10]. This group utilized heart rate variability as a measure
of autonomic control and found no statistically significant
difference between the AS versus the control group. An
acknowledged limitation was the young population in this
latter study, along with the fact that all patients were
under significant treatment with antiinflammatory agents,
hence hypothetically halting the advancement of autonomic
dysfunction [10].
Since most of the studies points towards early detection
and treatment of rheumatologic cardiac manifestations,
then early testing of these patients becomes important [8].
There are multiple modalities listed in the literature to aid
in the evaluation of cardiac manifestations of rheumatic
disease, such as utilization of 24-hour holter monitoring
and echocardiography [8]. In a study by Yildirir et al. they
demonstrate that a simple way to evaluate for the presence
of or propensity for developing arrhythmias is via measuring
QT dispersion. Yildirir et al. demonstrated that calculation
of the QT dispersion on a standard EKG is cheap, quick and
reveals valuable information regarding patient susceptibility
to arrhythmias. This approach is way more cost effective than
sending all patients off for holter monitoring amongst other
tests, and can easily be instituted in-office, whereby only
patients with increased arrhythmia risk can be referred for
further workup [8].
1.3. Myocardial Disease. It is widely demonstrated that the
myocardial dysfunction evident in patients with AS is that
of the diastolic variety, as opposed to systolic. For example,
in a study by Yildirir et al. they found significant diastolic
dysfunction in AS patients, particularly an abnormal relax-
ation pattern [2]. This was demonstrated via echocardiog-
raphy, by the statistically significant lower E-wave velocity
(early diastolic filling), higher A-wave velocity (late diastolic
filling), and overall low E/A ratio, which becomes evident in
patients with diastolic dysfunction [2]. Similarly, Gould et
al. evaluated the peak filling throughout exercise, along with
the time to achieve peak filling during strenuous activity via
radionucleotide angiography. Both of these measures were
considerably decreased in the patients with AS versus the
normal volunteers [11]. Hence, these findings also support
an overall decrease in compliance, and thus a reduction in
diastolic function.
Coronary flow reserve (CFR) is a measurement, which
evaluates the function of the coronaries in terms of their
microvascular circulation. This measure has been touted
by some experts as an important tool, holding prognostic
significance in the evolution of atherosclerosis in patients
[3]. Caliskan et al. recently used transthoracic Doppler
echocardiography (TTDE) to determine the CFR in AS
patients. Their findings were consistent with a significant
decrease in CFR in AS patients. Interestingly, the levels of
CRP and TNF-alpha correlated with the decline in CFR in
these patients [3].
Another study looked at an actual outcome, being
myocardial infarction, in patients with AS. They found a 2-3
fold increase in the rate of infarctions in the AS population
which they studied. Of note, amongst AS patients with and
without a myocardial infarct history, there was no difference
in the use and type of antirheumatic therapy [12]. This is
a significant observation; however, difficult to interpret as
the sample size is very limited (17 patients). A study with
multiple antirheumatic treatment arms would be ideal for
this type of analysis.
There has been research demonstrating that markers of
inflammation (i.e., CRP, IL-6) can reach a high enough level
to start disturbing lipid metabolism and diminishing insulin
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activity, hence causing insulin resistance and dyslipidemia,
leading to increased overall trend for atherogenecity [13]. In
a study by Divecha et al. they found a significant elevation in
IL-6 and CRP levels in patients with AS, over that of healthy
subjects. This is significant, as it has been reported that
even a subclinical but chronic elevation in the levels of these
markers accelerate risk of coronary heart disease, in patients
without autoimmune illnesses [13]. Furthermore given that
the clinical use of statins in a rheumatoid arthritis trial not
only helped with lipids but also led to reduced IL-6 levels,
so it is important to assess the role of these pharmacologic
agents in patients with AS and other spondyloarthritides
[13–15].
2. Pulmonary Manifestations of
Ankylosing Spondylitis
Introduction. Pulmonary involvement in ankylosing spon-
dylitis is an extra-articular manifestation of the disease that
was first described in 1941 in an article reviewing twenty
cases of ankylosing spondylitis [16] when two cases were
noted to have “healed apical tuberculosis”. The pulmonary
manifestations of the disease include fibrosis of the upper
lobes, interstitial lung disease, and ventilatory impairment
due to chest wall restriction, sleep apnea, and spontaneous
pneumothorax. The incidence of lung involvement in anky-
losing spondylitis has changed with the development of
high-resolution computed tomography (HRCT). Although
improved techniques in visualization of the lung have
allowed identification of more abnormalities of the lung
parenchyma associated with ankylosing spondylitis there is
little known about the natural history of such abnormalities
and the potential for therapies used in treatment of ankylos-
ing spondylitis to halt the progression of the lung disease.
2.1. High-Resolution Computed Tomography. The introduc-
tion of HRCT in pulmonary evaluation of ankylosing
spondylitis patients has shown that lung parenchymal
changes occur earlier and are more extensive than once
believed. In an evaluation of 26 patients with ankylosing
spondylitis for less than 5 years by Baser et al. HRCT
changes were seen in 13/25 (50%) of patients [17]. Upper
lobe fibrosis was identified in 1.3% of 2080 cases in a
retrospective review in 1977 but recent studies using HRCT
have shown a more extensive involvement of the lung [18].
The use of HRCT for evaluation of whole lung involvement
was first utilized by Casserly et al. in 1997 revealing lung
involvement in 19/26 (70%) ankylosing spondylitis patients
meeting the New York criteria for ankylosing spondylitis.
This uncontrolled study using HRCT to examining the lung
parenchyma saw a far larger number of abnormalities on
HRCT as compared with only 4/26 (15.3%) abnormal plain
X-rays in the same patients. Lung parenchymal abnormalities
observed included interstitial lung disease, emphysema,
apical fibrosis, mycetoma, and nonsepcific intestinal lung
disease [19]. Sampaio-Barros et al. evaluated pulmonary
involvement of ankylosing spondylitis in 52 patients with
no lung complaints and found that 40% had abnormalities
by HRCT compared with 8% by traditional chest X-ray
[20]. A similar finding was seen in a study by Turetschek et
al. in which 25 nonsmoking ankylosing spondylitis patients
underwent pulmonary function testing, chest X-ray, and thin
section CT with 15/21 (71%) of patients found to have
abnormalities on thin-section CT [21].
2.2. Apical Fibrosis and Interstitial Lung Disease. Upper lobe
fibrosis is a long recognized lung abnormality associated with
ankylosing spondylitis. The incidence of apical fibrosis in
ankylosing spondylitis is low with estimates ranging from
1.3–30% and has an association with longer disease duration
[22]. Apical fibrosis often appears greater than five years
after the start of the arthritic symptoms associated with
the disease [23]. The fibrosis can be unilateral or bilateral
in nature and is can be followed by cystic changes to
the lung [24]. The cause of the fibrosis is unknown but
recurrent aspiration leading to aspiration pneumonitis from
defective ventilation, alterations in apical mechanical stress
from a rigid thoracic spine, and recurrent impaired cough
secondary to alterations in respiratory mechanics have been
proposed [25, 26]. The abnormal lung parenchyma is a
fertile bed for superinfection with a variety of organisms
including atypical Mycobacterium, Mycobacterium tuberculo-
sis, Aspergillus, and Metschnikowia pulcherima [27–29]. The
distribution and appearance of the upper lobe abnormalities
in ankylosing spondylitis patients led many physicians
in the past to incorrectly diagnose these patients with
Mycobacterium tuberculosis. However, Ho et al. in a study
in Taiwan illustrated how differentiation between the two
often requires further diagnostic evaluation and a high index
of suspicion for infection when review of medical records
of 2136 ankylosing spondylitis patients in Taiwan revealed
63/2136 (2.9%) with apical fibrosis and chronic infection
from Mycobacterium Tuberculosis found in 41/63 (65%) of
those patients [30].
Interstitial lung disease (ILD), beyond apical fibrosis, is
now a recognized feature of pulmonary involvement in anky-
losing spondylitis as a result of improved visualization of the
lung parenchyma with HRCT [19]. Pathologic diagnosis of
ILD in the setting of ankylosing spondyltitis has rarely been
described due to a relative paucity of autopsy studies and the
cause of the ILD in this setting is still unclear. Case reports
and small series to date have shown evidence of chronic
inflammatory cell infiltrates and prominent interstitial fibro-
sis with elastic degeneration of collagen and hyaline by needle
biopsy and lobectomy examinations [31]. One case study
in 1971 described a patient with longstanding ankylosing
spondylitis admitted to the hospital with pancytopenia and
diffuse bilateral interstitial and alveolar infiltrates involving
the middle and upper lung fields [32]. Percutaneous lung
biopsy was performed and revealed interstitial pneumonitis
and fibrinous alveolitis.
Multiple studies have shown the association between ILD
and ankylosing spondylitis [17, 19, 33]. Baser et al. was
the first to show that these parenchymal changes can occur
early in the course of the disease, less than 5 years after the
start of ankylosing spondylitis symptoms, with parenchymal
abnormalities in 13/26 (50%) of all patients, 8/21 (38.1%) of
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asymptomatic patients, and in 5/5 (100%) of symptomatic
patients. The parenchymal abnormalities were broad includ-
ing emphysema, bronchiectasis, ground glass opacities, sep-
tal thickening, parenchymal micronodules, pleural thicken-
ing, parenchymal bands, and apical fibrosis with emphysema
being the most common abnormality seen in 9/21 (34.6%) of
patients. Similar findings were seen by Souza et al. with 11/17
(65%) of patients having evidence of ILD on HRCT [33]. In
an observational study of HRCT in ankylosing spondylitis,
Casserly et al. [19] found interstitial lung disease in 4/26
(16%) of ankylosing spondylitis patients. Simultaneous
evaluation with chest X-ray did not reveal any abnormalities
in any of the 4 patients found to have ILD on HRCT, however,
all 4 patients had abnormal pulmonary function testing.
2.3. Chest Wall Restriction and Ventilatory Abnormalities.
Restricted chest wall motion can lead to restricted pul-
monary function. Dorsal kyphosis from involvement of the
thoracic spine, costoverterbral, sternoclavicular, and ster-
nomanubrial joints leads to impairment of chest wall expan-
sion with breathing. Disease activity was not associated with
PFT abnormalities in one study evaluating 36 ankylosing
spondylitis patients compared to 34 controls who underwent
pulmonary function testing, smoking and quality of life
questionnaires [34]. The opposite was seen in an alternate
study by Maghraoui et al. of 55 ankylosing spondylitis
patients with a statistically significant correlation between
disease activity and PFT abnormalities [35]. The predomi-
nant abnormality on pulmonary function testing is a restric-
tive pattern and has been seen in numerous studies [31].
2.4. Spontaneous Pneumothorax. Spontaneous pneumotho-
rax is a very rare complication of ankylosing spondylitis,
with one retrospective review in Taiwan revealing a total
of 3/1028 cases for an incidence of 0.29% [36]. The
three cases were all seen in the setting of patients with
apical lung fibrotic changes confirmed by X-ray. Apical
lung abnormalities were seen in 22 patients total (22/1028,
2.1%), with spontaneous pneumothorax in 3 (3/22, 13.6%)
leading the authors to propose the primary risk factor
for spontaneous pneumothorax in ankylosing spondylitis
patients to be apical fibrosis. All three of the individuals who
had a spontaneous pneumothorax related to their disease
happened to be smokers. The contribution of smoking
to the risk of spontaneous pneumothorax in ankylosing
spondylitis patients is unclear given the small numbers
of spontaneous pneumothorax overall. Mean duration of
time from diagnosis of ankylosing spondylitis to timing of
spontaneous pneumothorax was 13.0±6.2 years. Recurrence
of spontaneous pneumothorax occurred in 2 out of 3 cases
with the third case undergoing talc pleurodesis at the first
occurrence leading the authors to conclude in their paper
with a recommendation that a prophylactic procedure to
prevent recurrence be considered at the first event. This was
echoed in a case report published by Kaneda et al. discussing
a case of recurrent bilateral repeat pneumothorax in a 53-
year-old male with ankylosing spondylitis who ultimately
required bilateral chemical pleurodesis [37].
2.5. Sleep Apnea. An increased incidence of sleep apnea in
patients with ankylosing spondylitis has been described
in several studies [38]. Fatigue is a common symptom
in ankylosing spondylitis and is a question on the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI)
used to determine the severity of an individual patients’
disease [39]. Obstructive sleep apnea was found in 12% of
patients in a small study by Erb et al. of 17 patients with
ankylosing spondylitis. This percentage was significantly
higher than the 1–4% seen in the general population.
Possible mechanisms for the cause of obstructive sleep apnea
in ankylosing spondylitis put forward by Erb et al. include
restriction of the oropharyngeal airway by compression from
cervical spine involvement or temporomandibular involve-
ment, restrictive pulmonary disease, or cervical spine disease
causing compression of the respiratory centers found in the
medulla [40]. In an attempt to further assess the prevalence
of obstructive sleep apnea in ankylosing spondylits, Solak et
al. [38] followed with a study of 31 ankylosing spondylitis
patient and subjected all patients to a polysomnography
evaluation and pulmonary function testing. Results revealed
7/31 (22.6%) found to have obstructive sleep apnea with
the mean age of those suffering from sleep apnea (43.4 ±
5.7) being statistically higher than those without sleep apnea
(33.2 ± 10.6). Pulmonary function testing of the same group
revealed a restrictive pattern in 12 (53.3%) of patients with
no increased incidence of pulmonary function abnormalities
in the group with obstructive sleep apnea as compared
to those without sleep apnea. An obstructive pattern on
pulmonary function testing was not observed in any patients.
Given the increased incidence of obstructive sleep apnea
in ankylosing spondylitis, formal sleep evaluation should be
considered in patients complaining of severe fatigue. Treat-
ment of obstructive sleep apnea in ankylosing spondylitis
is the same as for patients without ankylosing spondylitis
and includes CPAP (continuous positive airway pressure),
smoking cessation, and, if needed, weight loss to achieve a
normal body mass index.
Recent studies on sleep disturbance in ankylosing spon-
dylitis look at the effect of golimumab and adalimumab in
the reduction of sleep disturbance in patients suffering from
ankylosing spondylitis [41, 42]. Neither study addressed
the issue of sleep apnea specifically but instead looked at
validated measures of sleep disturbance and improvement of
these measures with the use of golimumab and adalimumab.
Deodhar et al. looked at sleep disturbance in patients treated
with golimumab 50 or 100 mg as compared with placebo
using the Jenkins Sleep Evaluation Questionnaire (JSEQ).
Patients on both doses of golimumab had a significant
greater improvement of their JSEQ compared to placebo
from baseline to week 12 and week 24 [41]. Rudwaleit
et al. performed a similar subanalysis of the RHAPSODY
(Review of Safety and Effectiveness with Adalimumab in
Patients with Active Ankylosing Spondylitis) to assess the
effect of adalimumab on sleep after 12 weeks of treatment
using the Medical Outcomes Sleep Study Scale (MOS-
SS) and showed that at week 12, adalimumab improved
sleep in all of the MOS-SS domains. Improvement was
similar in both patients with and without radiographically
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advanced ankylosing spondylitis [42]. While both of these
studies indicate ankylosing spondylitis improves patients’
assessment of sleep disturbance, interesting future studies
of antiTNFα agents in ankylosing spondylitis could include
assessment of sleep apnea in ankylosing spondylitis and
whether it can be reversed with antiTNFα therapy alone.
3. Conclusion
Knowledge on the various pulmonary and cardiac manifesta-
tions of ankylosing spondylitis has expanded throughout the
years with further study and improved imaging techniques.
The are many reports detailing pathophysiology, hypoth-
esized mechanisms leading to these derangements, and
estimated prevalence of such findings in the AS populations.
At this time, there are no clear guidelines regarding a step-
wise approach to screen these patients for cardiovascular or
pulmonary complications. While some investigators clearly
hint at the significance of detecting cardiopulmonary disease
as early as possible via clinical exams, lab tests, EKGs,
echocardiography, PFT, CT scan, there are some that remain
inconclusive in their recommendations.
A large prospective cohort study might be able to find
out if early detection of cardiopulmonary disease can change
patient’s prognosis and provide more concrete data by which
to recommend routine cardiac and pulmonary testing in
ankylosing spondylitis.
Similarly, Antitumor necrosis factor (TNF) α therapy
has now been used in the treatment of patients with anky-
losing spondylitis with good success in terms of improving
functionality, pain scores, and sleep disturbance [41–44].
Whether antiTNFα can halt or prevent the pulmonary or
cardiac manifestations of the disease will require a large
prospective trial in the future and must weigh the unknown
risks of prolonged treatment with antiTNFα agents against
treatment of ankylosing spondylitis and its extra-articular
manifestations.
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